Cardiac Arrhythmia and Conduction Disorders with MCC DRG Reimbursement

Summary & Overview

Cardiac Arrhythmia and Conduction Disorders with MCC: Inpatient Reimbursement Overview

DRG 308 encompasses hospital stays for cardiac arrhythmia and conduction disorders accompanied by a Major Complication or Comorbidity, reflecting higher clinical complexity and resource needs. Proper classification influences inpatient reimbursement under Medicare by assigning a higher payment weight for admissions with major complications or comorbidities.

Cardiac Arrhythmia and Conduction Disorders with MCCDRG Cardiac Arrhythmia and Conduction Disorders with MCCDRG 308Diagnosis-Related GroupInpatient ReimbursementMedicareCardiologyElectrophysiologyPacemakerArrhythmia Management

DRG 308 Overview

DRG 308 covers inpatient admissions for cardiac arrhythmia and conduction disorders with a Major Complication or Comorbidity. This group includes complex rhythm disturbances and conduction system diseases that require significant inpatient evaluation, monitoring, and interventions. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases relative resource use and influences the Diagnosis-Related Group assignment and reimbursement weight. Accurate coding of the underlying arrhythmia, conduction disorder, and any Major Complication or Comorbidity is therefore essential for proper inpatient payment.

National Payment Rates

Across commercial payers the rate range runs from about $11K to $44K, with the widest spread between Anthem (max $44K) and BCBS (min around $11K). Commercial medians cluster between $18K and $22K, while mean values vary payer-to-payer; see the table and chart below for payer-level detail. The payer-level variation indicates notable dispersion in negotiated rates across major insurers.

Mean Rates by Payer — National — DRG 308

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($11.0k), average submitted covered charges ($53.3k), average Medicare payment amount ($8.9k), and total discharges (49.8k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska payer rates for DRG 308 span from $19K to $29K across reported payers, with Cigna at the high end and Anthem and Blue Cross Blue Shield clustered at the low end. This range is relatively compressed versus national distributions, and Cigna’s mean of $29K represents the most notable upward deviation from national averages. Reference the table and chart below for payer-specific percentiles and distribution details.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of $29K, while Anthem and Blue Cross Blue Shield are the lowest at $19K.
The state range is narrow ($19K–$29K) compared with broader national variability, and Alaska’s Cigna mean ($29K) is notably above typical national means for several payers.

Clinical Trials

Acute rhythm stabilization and emergent management trials: investigations focus on immediate interventions for hospitalized patients presenting with life-threatening arrhythmias or conduction blocks, such as protocolized use of electrical cardioversion, temporary pacing strategies, and optimized antiarrhythmic drug sequencing in the intensive care or telemetry setting. These studies enroll patients admitted with hemodynamically unstable atrial or ventricular arrhythmias, high-degree AV block, or peri-procedural conduction complications, and compare time-to-rhythm-control, complication rates, and short-term mortality. Results inform inpatient care pathways, resource utilization (ICU stays, telemetry monitoring, device placement), and payer decisions about coverage of acute interventions and hospital-level quality metrics.
Comparative effectiveness trials of device and procedure strategies for secondary prevention: randomized or pragmatic studies compare outcomes of different definitive in-hospital procedures such as permanent pacemaker implantation versus conservative management for advanced conduction disease, or timing and indications for implantable cardioverter-defibrillator placement after arrhythmic events. These trials typically enroll stabilized inpatients with documented conduction disorders or life-threatening ventricular arrhythmias who are candidates for device therapy, assessing readmission rates, recurrent arrhythmia events, functional status, and downstream costs over months to years. Evidence from these studies guides clinicians and payers on which procedural strategies yield the best balance of clinical benefit, complication risk, and long-term healthcare expenditures for patients in this DRG.
Post-discharge outcomes and care-transition research: cohort studies and interventional trials examine discharge planning, remote monitoring, medication reconciliation, and outpatient follow-up models for patients hospitalized with arrhythmias or conduction disorders to reduce readmissions and adverse events. These studies enroll typical post-acute patients—often older adults with comorbid heart disease, atrial fibrillation, or device implants—and measure outcomes such as 30- and 90-day readmission, emergency visits, adherence to anticoagulation or antiarrhythmic therapy, and patient-reported quality of life. Findings are directly relevant to hospitals and payers seeking to optimize transitions of care, lower preventable utilization, and design reimbursement or care-management programs targeted at this high-risk DRG population.

Related Codes

305-HYPERTENSION-WITHOUT-MCC

Hypertension without MCC: Inpatient Reimbursement Overview

254-OTHER-VASCULAR-PROCEDURES-WITHOUT-CC-MCC

Other Vascular Procedures without CC/MCC: Inpatient Reimbursement Overview

298-CARDIAC-ARREST-UNEXPLAINED-WITHOUT-CC-MCC

Cardiac Arrest, Unexplained without CC/MCC: Inpatient Reimbursement Overview

213-ENDOVASCULAR-ABDOMINAL-AORTA-WITH-ILIAC-BRANCH-PROCEDURES

Endovascular Abdominal Aorta with Iliac Branch Procedures: Inpatient Reimbursement Overview

252-OTHER-VASCULAR-PROCEDURES-WITH-MCC

Other Vascular Procedures with MCC: Inpatient Reimbursement Overview

323-CORONARY-INTRAVASCULAR-LITHOTRIPSY-WITH-INTRALUMINAL-DEVICE-WITH-MCC

Coronary Intravascular Lithotripsy with Intraluminal Device with MCC: Inpatient Reimbursement Overview

228-OTHER-CARDIOTHORACIC-PROCEDURES-WITH-MCC

Other Cardiothoracic Procedures with MCC: Inpatient Reimbursement Overview

283-ACUTE-MYOCARDIAL-INFARCTION-EXPIRED-WITH-MCC

Acute Myocardial Infarction, Expired with MCC: Inpatient Reimbursement Overview

282-ACUTE-MYOCARDIAL-INFARCTION-DISCHARGED-ALIVE-WITHOUT-CC-MCC

Acute Myocardial Infarction: Inpatient Reimbursement Overview

306-CARDIAC-CONGENITAL-AND-VALVULAR-DISORDERS-WITH-MCC

Cardiac Congenital and Valvular Disorders with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$11K	$53K	$8.9K	50K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 308

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of $29K, while Anthem and Blue Cross Blue Shield are the lowest at $19K.
The state range is narrow ($19K–$29K) compared with broader national variability, and Alaska’s Cigna mean ($29K) is notably above typical national means for several payers.

Clinical Trials

Acute rhythm stabilization and emergent management trials: investigations focus on immediate interventions for hospitalized patients presenting with life-threatening arrhythmias or conduction blocks, such as protocolized use of electrical cardioversion, temporary pacing strategies, and optimized antiarrhythmic drug sequencing in the intensive care or telemetry setting. These studies enroll patients admitted with hemodynamically unstable atrial or ventricular arrhythmias, high-degree AV block, or peri-procedural conduction complications, and compare time-to-rhythm-control, complication rates, and short-term mortality. Results inform inpatient care pathways, resource utilization (ICU stays, telemetry monitoring, device placement), and payer decisions about coverage of acute interventions and hospital-level quality metrics.
Comparative effectiveness trials of device and procedure strategies for secondary prevention: randomized or pragmatic studies compare outcomes of different definitive in-hospital procedures such as permanent pacemaker implantation versus conservative management for advanced conduction disease, or timing and indications for implantable cardioverter-defibrillator placement after arrhythmic events. These trials typically enroll stabilized inpatients with documented conduction disorders or life-threatening ventricular arrhythmias who are candidates for device therapy, assessing readmission rates, recurrent arrhythmia events, functional status, and downstream costs over months to years. Evidence from these studies guides clinicians and payers on which procedural strategies yield the best balance of clinical benefit, complication risk, and long-term healthcare expenditures for patients in this DRG.
Post-discharge outcomes and care-transition research: cohort studies and interventional trials examine discharge planning, remote monitoring, medication reconciliation, and outpatient follow-up models for patients hospitalized with arrhythmias or conduction disorders to reduce readmissions and adverse events. These studies enroll typical post-acute patients—often older adults with comorbid heart disease, atrial fibrillation, or device implants—and measure outcomes such as 30- and 90-day readmission, emergency visits, adherence to anticoagulation or antiarrhythmic therapy, and patient-reported quality of life. Findings are directly relevant to hospitals and payers seeking to optimize transitions of care, lower preventable utilization, and design reimbursement or care-management programs targeted at this high-risk DRG population.